



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/007,768	11/08/2001	Aristo Vojdani	IMSCI2.003A	3144
20995 75	90 06/15/2004		EXAM	INER
	RTENS OLSON & BE	NGUYEN, BAO THUY L		
2040 MAIN STREET FOURTEENTH FLOOR			ART UNIT	PAPER NUMBER
IRVINE, CA 92614			1641	
			DATE MAILED, 04/15/200	4

DATE MAILED: 06/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Astis a Comment	10/007,768	VOJDANI, ARISTO			
Office Action Summary	Examiner	Art Unit			
	Bao-Thuy L. Nguyen	1641			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet wi	th the correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	I36(a). In no event, however, may a relay within the statutory minimum of thirt will apply and will expire SIX (6) MON e, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 08 A	lovember 2001.				
2a) ☐ This action is FINAL . 2b) ☒ This	This action is FINAL . 2b)⊠ This action is non-final.				
3) Since this application is in condition for allowa closed in accordance with the practice under the second secon	•	•			
Disposition of Claims					
 4) ☐ Claim(s) 1-7 is/are pending in the application. 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-7 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or 					
Application Papers					
9)☐ The specification is objected to by the Examine	er.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	is have been received. Is have been received in A Inity documents have been u (PCT Rule 17.2(a)).	pplication No received in this National Stage			
Attacker ant/a)		•			
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 3/15/02.	Paper No(s)/Mail Date formal Patent Application (PTO-152)			

DETAILED ACTION

Response to Amendment

1. Applicant's preliminary amendment filed July 02, 2002 has been received. Claims 1-7 are pending.

Claim Rejections - 35 USC § 112, second paragraph

2. Claims 1-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is confusing with respect to the recitation of "a corresponding recombinant antigen or synthetic peptide" because recombinant antigen and synthetic peptides are not found in patient samples.

Claim 1 is further confusing because the preamble of the claim does not correlate with the analysis of the detected result. For example, the preamble recites a method for diagnosing the exposure to infectious agents; however, the detected result is recited as indicating a presence or possibility of an infection. It is noted that exposure to infectious agents does not necessarily leads to an infection.

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Application/Control Number: 10/007,768 Page 3

Art Unit: 1641

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 1-7 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Blaser et al (US 5,200,344).

Blaser discloses an ELISA for the diagnosis of bacterial infection by detecting antibodies (e.g. IgA) to said bacteria in saliva fluids. See column 4, line 59 through column 5, line 20. Blaser teaches the formation of a complex between a bacterial antigen and IgA antibody, and stated that when such complex exceeds a predetermined positive threshold value, the test is considered positive for the presence of the antibody. See also column 9, lines 5-36 and column 10. Blaser teaches that by using acid-extracted proteins, antibodies to 5 different strains of *H. pylori* can be detected. See column 14, lines 16-44.

3. Claims 1-7 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Goldstein et al (US 5,103,836).

Goldstein discloses an ELISA for the diagnosis of infectious agents such as bacteria and viruses by detecting IgA antibodies against said infectious agents in sample fluids such as saliva. Specifically, Goldstein teaches the detection of antibodies to hepatitis A as well as HIV. Goldstein teaches comparing the results of seropositive individuals with seronegative individuals as well as cut off values for certain tests. See column 10, example 1.

Conclusion

4. No claim is allowed.

Application/Control Number: 10/007,768

Art Unit: 1641

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao-Thuy L. Nguyen whose telephone number is (571) 272-0824. The examiner can normally be reached on Tuesday and Thursday from 9:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

BAO-THUY L. NGUYEN
PRIMARY EXAMINER

6/9/04